Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells
- PMID: 17392506
- PMCID: PMC1896112
- DOI: 10.1182/blood-2006-12-062422
Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells
Abstract
Expression of the PD-1 receptor on T cells has been shown to provide an important inhibitory signal that down-modulates peripheral effector responses in normal tissues and tumors. Furthermore, PD-1 up-regulation on chronically activated T cells can maintain them in a partially reversible inactive state. The function of PD-1 in the very early stages of T-cell response to antigen in vivo has not been fully explored. In this study, we evaluate the role of PD-1 and its 2 B7 family ligands, B7-H1 (PD-L1) and B7-DC (PD-L2), in early fate decisions of CD8 T cells. We show that CD8 T cells specific for influenza hemagglutinin (HA) expressed as a self-antigen become functionally tolerized and express high levels of surface PD-1 by the time of their first cell division. Blockade of PD-1 or B7-H1, but not B7-DC, at the time of self-antigen encounter mitigates tolerance induction and results in CD8 T-cell differentiation into functional cytolytic T lymphocytes (CTLs). These findings demonstrate that, in addition to modulating effector functions in the periphery, B7-H1:PD-1 interactions regulate early T-cell-fate decisions.
Figures
Similar articles
-
Target-dependent B7-H1 regulation contributes to clearance of central nervous system infection and dampens morbidity.J Immunol. 2009 May 1;182(9):5430-8. doi: 10.4049/jimmunol.0803557. J Immunol. 2009. PMID: 19380790 Free PMC article.
-
The programmed death-1 ligand 1:B7-1 pathway restrains diabetogenic effector T cells in vivo.J Immunol. 2011 Aug 1;187(3):1097-105. doi: 10.4049/jimmunol.1003496. Epub 2011 Jun 22. J Immunol. 2011. PMID: 21697456 Free PMC article.
-
Cutting Edge: Programmed death (PD) ligand-1/PD-1 interaction is required for CD8+ T cell tolerance to tissue antigens.J Immunol. 2006 Dec 15;177(12):8291-5. doi: 10.4049/jimmunol.177.12.8291. J Immunol. 2006. PMID: 17142723
-
PD-1 and its ligands in tolerance and immunity.Annu Rev Immunol. 2008;26:677-704. doi: 10.1146/annurev.immunol.26.021607.090331. Annu Rev Immunol. 2008. PMID: 18173375 Free PMC article. Review.
-
The right place at the right time: novel B7 family members regulate effector T cell responses.Curr Opin Immunol. 2002 Jun;14(3):384-90. doi: 10.1016/s0952-7915(02)00342-4. Curr Opin Immunol. 2002. PMID: 11973139 Review.
Cited by
-
Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer.Clin Cancer Res. 2013 Mar 1;19(5):1021-34. doi: 10.1158/1078-0432.CCR-12-2063. Clin Cancer Res. 2013. PMID: 23460533 Free PMC article.
-
Specific CD8(+) T cell response immunotherapy for hepatocellular carcinoma and viral hepatitis.World J Gastroenterol. 2016 Jul 28;22(28):6469-83. doi: 10.3748/wjg.v22.i28.6469. World J Gastroenterol. 2016. PMID: 27605882 Free PMC article. Review.
-
A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells.Blood. 2008 Jan 1;111(1):251-9. doi: 10.1182/blood-2007-03-081646. Epub 2007 Oct 1. Blood. 2008. PMID: 17909080 Free PMC article.
-
Neoadjuvant PD-1 blockade in lung cancer: we're not in Kansas anymore.J Thorac Dis. 2018 Aug;10(8):4686-4688. doi: 10.21037/jtd.2018.07.98. J Thorac Dis. 2018. PMID: 30233839 Free PMC article. No abstract available.
-
B7-H1 blockade increases survival of dysfunctional CD8(+) T cells and confers protection against Leishmania donovani infections.PLoS Pathog. 2009 May;5(5):e1000431. doi: 10.1371/journal.ppat.1000431. Epub 2009 May 15. PLoS Pathog. 2009. PMID: 19436710 Free PMC article.
References
-
- Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev Immunol. 2005;23:515–548. - PubMed
-
- Zhu B, Guleria I, Khosroshahi A, et al. Differential role of programmed death-ligand 1 [corrected] and programmed death-ligand 2 [corrected] in regulating the susceptibility and chronic progression of experimental autoimmune encephalomyelitis [published erratum appears in J Immunol. 2006;176:5683]. J Immunol. 2006;176:3480–3489. - PubMed
-
- Curiel TJ, Wei S, Dong H, et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med. 2003;9:562–567. - PubMed
-
- Hirano F, Kaneko K, Tamura H, et al. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res. 2005;65:1089–1096. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials